Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities

BACKGROUND: Elderly patients (≥65 yr) with advanced prostate cancer and cardiovascular disease (CVD) conditions are often excluded from clinical trials of abiraterone acetate (AA) or enzalutamide (ENZ). Consequently, little is known about the effects of these medications on these vulnerable patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur Urol
Main Authors: Lu-Yao, Grace, Nikita, Nikita, Keith, Scott W., Nightingale, Ginah, Gandhi, Krupa, Hegarty, Sarah E., Rebbeck, Timothy R., Chapman, Andrew, Kantoff, Philip W., Cullen, Jennifer, Gomella, Leonard, Kelly, William Kevin
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980462/
https://ncbi.nlm.nih.gov/pubmed/31420248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.07.031
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki